Levofloxacin efficacy in the treatment of community-acquired legionellosis

Chest

Volumn 125, Issue 6, 2004, Pages 2135-2139

  Yu, Victor L ^a   Greenberg, Richard N ^b   Zadeikis, Neringa ^c   Stout, Janet E ^a   Khashab, Mohammed M ^c   Olson, William H ^c   Tennenberg, Alan M ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Clinical efficacy; Community acquired pneumonia; Legionella; Levofloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CEFUROXIME AXETIL; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN;

ADULT; AGE DISTRIBUTION; ANXIETY; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INSOMNIA; LEGIONELLA; LEGIONNAIRE DISEASE; MAJOR CLINICAL STUDY; MORTALITY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING;

EID: 2942726091     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.6.2135     Document Type: Article

References (25)

1. Roig J, Domingo C, Morera J. Legionnaires disease. Chest 1994; 105:1817-1825
2. Nguyen MLT, Yu VL. Legionella infection. Clin Chest Med 1991; 12:257-268
3. Baltch AL, Smith RP, Franke MA, et al. Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila. Antimicrob Agents Chemother 1998; 42:3153-3156
4. Edelstein PH. Antimicrobial chemotherapy for Legionnaires disease: a review. Clin Infect Dis 1995; 21(suppl 3):S265-S276
5. Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires disease: risk factors for morbidity and mortality. Arch Intern Med 1994; 154:2417-2422
6. Stout JE, Yu VL. Legionellosis. N Engl J Med 1997; 337:682-687
7. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for die management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-382
8. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754
9. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infection 2002; 8:214-221
10. Stout JE, Arnold B, Yu VL. Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells. Diagn Microbiol Infect Dis 1998; 30:37-43
11. Smith RP, Baltch AL, Franke M, et al. Effect of levofloxacin, erythromycin or rifampicin pretreatment of growth of Legionella pneumophila in human monocytes. J Antimicrob Chemother 1997; 40:673-678
12. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119:1114-1122
13. Wright DH, Brown GH, Peterson ML, et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46:669-683
14. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-12
15. Pedro-Botet M, Vilaseca Z, Sopena N, et al. Erythromycin versus fluoroquinolones in the treatment of Legionnaires disease. Presented at the 41st Interscience Conference for Antimicrobial Agents and Chemotherapy, Chicago, IL, September 22 to 25, 2001; abstract L-878
16. Mulazimoglu L, Yu VL. Can Legionnaires disease be diagnosed by clinical criteria? A critical review. Chest 2001; 120:1049-1053
17. Fogarty CM, Sullivan JG, Chattman MS, et al. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. Infect Dis Clin Pract 1998; 7:400-407
18. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41:1965-1972
19. Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin vs ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin/clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004; 38(Suppl):S16-S23
20. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250
21. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-760
22. Salkind AR, Cuddy PG, Foxworth JW. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother 2002; 36:1938-1943
23. Muder RR, Yu VL, Fang G-D. Community-acquired Legionnaires disease. Semin Respir Infect 1989; 4:32-39
24. Marston BJ, Plouffe JF, Breiman RF, et al. Preliminary findings of a community-based pneumonia incidence study. In: Barberee JM, Breiman RF, Dufour AP, eds. Legionella: current status and emerging perspectives. Washington, DC: American Society for Microbiology, 1993; 36-37
25. Squier C, Lin YE, Stout JE. Waterborne pathogens: Legionella and other opportunistic pathogens. Presented at the American Society of Healthcare Engineers of the American Hospital Association, July 16 to 18, 2001; Tampa, FL; abstract 055995